Allogene Therapeutics Inc (ALLO)
2.98
+0.02
(+0.68%)
USD |
NASDAQ |
May 15, 16:00
2.96
-0.02
(-0.67%)
After-Hours: 17:56
Allogene Therapeutics Cash from Financing (Quarterly): 1.65M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.65M |
| December 31, 2023 | 0.155M |
| September 30, 2023 | 4.285M |
| June 30, 2023 | 89.52M |
| March 31, 2023 | 1.731M |
| December 31, 2022 | 0.046M |
| September 30, 2022 | 1.066M |
| June 30, 2022 | 0.024M |
| March 31, 2022 | 1.814M |
| December 31, 2021 | 0.322M |
| September 30, 2021 | 2.383M |
| June 30, 2021 | 3.214M |
| March 31, 2021 | 6.044M |
| Date | Value |
|---|---|
| December 31, 2020 | 12.98M |
| September 30, 2020 | 3.852M |
| June 30, 2020 | 600.18M |
| March 31, 2020 | 16.59M |
| December 31, 2019 | 56.47M |
| September 30, 2019 | 1.566M |
| June 30, 2019 | 0.236M |
| March 31, 2019 | 0.684M |
| December 31, 2018 | 344.52M |
| September 30, 2018 | 274.06M |
| June 30, 2018 | 152.60M |
| March 31, 2018 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.024M
Minimum
Jun 2022
600.18M
Maximum
Jun 2020
40.21M
Average
2.098M
Median
Cash from Financing (Quarterly) Benchmarks
| Agenus Inc | 14.83M |
| BioCryst Pharmaceuticals Inc | -1.048M |
| Novavax Inc | 5.886M |
| Vaxart Inc | -0.066M |
| aTyr Pharma Inc | 7.73M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -55.90M |
| Cash from Investing (Quarterly) | 22.13M |
| Free Cash Flow | -227.48M |
| Free Cash Flow Per Share (Quarterly) | -0.3306 |
| Free Cash Flow to Equity (Quarterly) | -55.91M |
| Free Cash Flow Yield | -46.83% |